2012;14(5):411-417. 1 Expanding upon the current Omnipod DASH Insulin Management System, Insulet has developed and is currently in clinical trials for its Omnipod Horizon™ AID System. In a major splash at the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid, Spain, Insulet unveiled partnerships with continuous glucose monitor companies Abbott and Dexcom.Insulet announced plans to integrate … The trial was expected to resume by the end of April; now with delays around COVID-19, Insulet is expecting the trial to resume sometime in June. Novel Bluetooth-Enabled Tubeless Insulin Pump: Innovating Pump Therapy for Patients in the Digital Age. Zisser HC, Bevier W, Dassau E, Jovanovic L. Siphon effects on continuous subcutaneous insulin infusion pump delivery performance. Insulet partners with Abbott and Dexcom to develop Omnipod Horizon systems. This will be followed by a 94-day (13-week) hybrid closed-loop phase, conducted in an outpatient setting where subjects, or their caregivers, will manage their diabetes at home using the Omnipod Horizon™ Automated Glucose Control System. 2020;22(3):174-184. Forlenza GP, Buckingham BA, Christiansen MP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. Improved Open-Loop Glucose Control With Basal Insulin Reduction 90 Minutes Before Aerobic Exercise in Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion. A 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Epub. Measure of serious device-related adverse events, Glucose metric from study continuous glucose monitoring system (CGM), Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the standard deviation (SD), Glucose metric from study continuous glucose monitoring system (CGM)-measured glucose variability with the coefficient of variation (CV), Measurement of glucose management using overall glucose averages. Please remove one or more studies before adding more. All other trademarks are the property of their respective owners. By Eliza Skoler, Rhea Teng, and Albert Cai. 2019;21(5):265-272. Diabetes Technol Ther.2018;20(9):585-595. COVID-19 is an emerging, rapidly evolving situation. Everyone now has the opportunity to help make the future better for people living with diabetes. Sherr JL, Buckingham BA, Forlenza GP, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett LM, Layne JE, Ly TT. single-arm, multi-center, prospective clinical study: Masking: None (Open Label) Primary Purpose: Treatment: Official Title: Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Children With Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort: Actual Study Start Date : September 8, 2020 SAN FRANCISCO – Insulet Corp. aims to get an FDA approval this year and launch its first interoperable device, the cord-free, wearable insulin device Omnipod Horizon. This is a single-arm, multi-center, prospective clinical study. The study demonstrated that the Omnipod Horizon System performed well and was safe for over five days of use in adults, adolescents, and children with type 1 diabetes. COVID-19: view a video response from our CEO, Submit your research proposal through our Investigator Initiated Trial Portal, https://www.liebertpub.com/doi/10.1089/dia.2018.0364, https://care.diabetesjournals.org/content/42/5/824, https://journals.sagepub.com/doi/full/10.1177/1932296818804802, https://journals.sagepub.com/doi/full/10.1177/1932296817735341, https://journals.sagepub.com/doi/full/10.1177/1932296816638674, https://www.liebertpub.com/doi/10.1089/dia.2016.0239?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. Polonsky WH, Hessler D, Layne JE, Zisser H. Impact of the Omnipod® Insulin Management System on Quality of Life: A Survey of Current Users. Insulet to pause Omnipod Horizon … Masking: None (Open Label) Primary Purpose: Treatment: Official Title: Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes: Actual Study Start Date : December 30, 2019: Actual Primary Completion Date : Subjects may be recruited from the Omnipod Horizon Pivotal Study (G190270) prior to their recommencement of … Please see the following information from the ClinicalTrials.gov website to learn more about clinical trials in progress. 2020;22(3):434-441. Diabetes Technol Ther. Diabetes Obes Metab. Layne JE, Parkin CG, Zisser H. Efficacy of a Tubeless Patch Pump in Patients With Type 2 Diabetes Previously Treated With Multiple Daily Injections. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study. These are the first outpatient results the public has seen. Insulet said it plans to pause a pivotal clinical study of its upcoming wearable insulin pump due to an anomaly in the device’s software. 2016 Layne JE, Parkin CG, Zisser H. Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion. Ly TT, Layne JE, Huyett LM, Nazzaro D, O’Connor JB. J Diabetes Sci Technol. Launch of Omnipod Horizon is expected in the first half of 2021, a delay from original plans to launch by the end of this year. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation. Diabetes Technol Ther. J Diabetes Sci Technol. During the hybrid closed-loop phase, a subset of subjects will participate in 2-days of supervised meal and exercise challenges. Omnipod Horizon™ Automated Glucose Control System Preschool Cohort Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. We partner with researchers and centers of excellence worldwide to conduct studies in patients with diabetes of various ages using Omnipod DASH® Insulin Management System or Omnipod® Insulin Management System and other products in development. Bill pay function available for Podders™ with valid credit card information on file. Talk with your doctor and family members or friends about deciding to join a study. Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. The objective for the study was to assess the safety and efficacy of the Omnipod Horizon™ Automated Glucose Control System. Pediatr Diabetes. Novel methodology to determine the accuracy of the OmniPod insulin pump: a key component of the artificial pancreas system. Omnipod, the Omnipod logo, DASH, the DASH logo, HORIZON, the HORIZON Logo, Omnipod DISPLAY, Omnipod VIEW, Omnipod DEMO, Podder, Toby the Turtle, PodderCentral, the PodderCentral logo, and PodderTalk are trademarks or registered trademarks of Insulet Corporation. Zaharieva DP, McGaugh S, Pooni R, Vienneau T, Ly T, Riddell MC. Study record managers: refer to the Data Element Definitions if submitting registration or results information. In Silico Modeling of Minimal Effective Insulin Doses Using the UVA/PADOVA Type 1 Diabetes Simulator. Lebenthal Y, Lazar L, Benzaquen H, Shalitin S, Phillip M. Patient perceptions of using the OmniPod system compared with conventional insulin pumps in young adults with type 1 diabetes. J Diabetes Sci Technol. All subjects wearing the Omnipod Horizon™ Automated Glucose Control System using the closed-loop algorithm. Insulet’s hybrid closed loop — Omnipod Horizon — is gearing up to enter Phase 3 clinical trials later this year and aiming for a public release in the second half of 2020. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. It is designed to be compatible with the Dexcom G6 and is the result of a partnership between the two companies. The … Danne T, Schwandt A, Biester T, Heidtmann B, Rami-Merhar B, Haberland H, Müther S, Khodaverdi S, Haak T, Holl RW, for the DPVI. GLP1 agonist, SGLT2 inhibitor, DPP-4 inhibitor, pramlintide), Thyroid Stimulating Hormone (TSH) is outside of normal range with clinical signs of hypothyroidism or hyperthyroidism, Currently participating or plans to participate in another clinical study using an investigational drug or device other than the Omnipod Horizon™ Automated Glucose Control System during this study period, Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment. 2019;21(6):313-321. This information allowed us to quickly identify, investigate, and decide to correct the issue. Pivotal Omnipod Horizon™ Automated Glucose Control System 1 (on-going trial) Patient with Type 1 diabetes will undergo a 14-day outpatient, standard therapy phase during which sensor and … Buckingham BA, Christiansen MP, Forlenza GP, Wadwa RP, Peyser TA, Lee JB, O'Connor J, Dassau E, Huyett LM, Layne JE, Ly TT. Patient with Type 1 diabetes will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. Clinical Trials and Research Insulet’s research program focuses on clinical outcomes, quality of life, and our commitment to innovation. This information allowed us to quickly identify, investigate, and decide to correct the issue. Especially important for PWD who lean toward “tubeless” insulin delivery systems. After the conclusion of the three presentations on Medtronic’s 780G system, Dr. Bruce Buckingham from Stanford University presented the pre-pivotal trial results from Insulet’s Omnipod 5, powered by Horizon. The intended design of the technology is to leverage glucose values from a CGM to … The experience highlights the benefits of our significant investment in mobile and cloud technology, which enable our engineers to monitor enormous amounts of information in real-time from the Omnipod Horizon clinical trials. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04476472. 2020. U.S. Department of Health and Human Services, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Omnipod ® Horizon ™ System Significantly Improves Glycemic Control in Patients with Type 1 Diabetes. The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license. Diabetes Technol Ther. OmniPod Artificial Pancreas System Clinical Trial By Lisa Foster-McNulty, MSN, RN, CDE If you are interested in participating in a study involving the use of the OmniPod Horizon Hybrid Closed Loop System, you might want to check out ClinicalTrials.gov to see if you qualify. Campos-Nanez E, Layne JE, Zisser HC. J Diabetes Sci Technol. Omnipod 5, Powered by Horizon pre-pivotal trial results. Read our, ClinicalTrials.gov Identifier: NCT04476472, Interventional J Diabetes Sci Technol. Diabetes Technol Ther. Glycemic Control and Factors Impacting Treatment Choice in Tubeless Insulin Pump Users: A Survey of the T1D Exchange Glu Online Community. Why Should I Register and Submit Results? This is a single-arm, multi-center, prospective clinical study. Blevins T, Lane W, Rodbard D, Sindelar DK, Fan L, Ellinor KS, Ilag L, Ly TT, Johnson J. Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM findings from the VIVID study. T1D Exchange ... ©2018-2020 Insulet Corporation. Subjects, or their caregivers, will manage their diabetes at home per their usual routine using the study continuous glucose monitoring system (CGM) and remain on current multiple daily injections (MDI) or pump therapy. Lag Time Remains with Newer Real-Time Continuous Glucose Monitoring Technology During Aerobic Exercise in Adults Living with Type 1 Diabetes. By Albert Cai. The study demonstrated that the investigational Omnipod Horizon System performed well and was safe for up to four days of use in children as young as two years old with type 1 diabetes. Diabetes Care. BILLERICA, Mass.--(BUSINESS WIRE)--Jun. *The Omnipod HORIZON™ System is an investigational device, limited by United States Law to Investigational Use Insulet collaboration with Tidepool Loop Program Insulet announced it will be working with Tidepool, a non-profit organization that is working on an open-source, iOS based app and algorithm. ©2018-2020 Insulet Corporation. 2019;13(1):20-26. Listing a study does not mean it has been evaluated by the U.S. Federal Government. "Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes," said Patrick Sullivan, President and Chief Executive Officer. To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® Insulin Management System, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type 1 diabetes consuming high fat meals and undertaking moderate intensity exercise. 2018;19(5):979-984. A medical condition, which in the opinion of the investigator, would put the subject at an unacceptable safety risk, History of severe hypoglycemia in the past 6 months, History of DKA in the past 6 months, unrelated to an intercurrent illness, infusion set failure or initial diagnosis, Diagnosed with hemophilia or any other bleeding disorders, Plans to receive blood transfusion over the course of the study, Clinical evidence of acute or chronic kidney disease (e.g.  (Clinical Trial), single-arm, multi-center, prospective clinical study, Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Children With Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort, Palo Alto, California, United States, 94305, New Haven, Connecticut, United States, 06511, Boston, Massachusetts, United States, 02215, Saint Louis Park, Minnesota, United States, 55416, Charlottesville, Virginia, United States, 22904. estimated GFR < 45) or currently on hemodialysis, Has taken oral or injectable steroids within the past 8-weeks or plans to take oral or injectable steroids during the course of the study, Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement, Plans to use insulin other than U-100 insulin intended for use in the study device during the course of the study, Use of non-insulin anti-diabetic medication other than metformin (e.g. This was followed by a 14-day hybrid closed-loop phase conducted in both a hotel/rental house setting and an outpatient setting. Novel Bluetooth-Enabled Tubeless Insulin Pump: A User Experience Design Approach for a Connected Digital Diabetes Management Platform. Pillalamarri SS, Huyett LM, Abdel-Malek A. The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. The Endocrine Society is the world’s first and largest organization dedicated to research on hormones and the clinical practice of endocrinology. Dive Brief: Insulet is pausing the clinical trial it hoped would support commercialization of its new automated insulin delivery system Horizon by year's end after discovering a "software anomaly" that could result in incorrect insulin dosing. 2017;11(1):178-179. Grunberger G, Bhargava A, Ly T, Zisser H, Ilag LL, Malone J, Fan L, Zhang S, Johnson J. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting, and an optional 6-month extension phase. An early investigation on the safety and performance of an Automated Glucose Control (AGC) algorithm using the Omnipod® Insulin Management System and gather clinical data that will be used to make improvements or modifications to the algorithm for subsequent studies in adults, adolescents and children with type 1 diabetes. This will be followed by a 5-day/4-night, or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting. The hybrid closed-loop phase will begin on Study Day 1. VOLUNTEER in OmniPod Horizon "Closed-Loop" Clinical Trial - Technology & Management - JDRF TypeOneNation Community Forum. Masking: None (Open Label) Primary Purpose: Treatment: Official Title: Prepivotal Evaluation of the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes: Actual Study Start Date : December 15, 2019: Actual Primary Completion Date : To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. 2016;10(5):1130-5. Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. Insulet Corporation’s research program focuses on clinical outcomes, quality of life, and our commitment to innovation. We partner with researchers and centers of excellence worldwide to conduct studies in patients with diabetes of various ages using our Omnipod ® System and other products in development. Diabetes Technol Ther. The enthusiasm from our trial participants has been overwhelmingly positive and we are excited for what Omnipod Horizon will offer our customers." Diabetes Care. COVID-19: view a video response from our CEO  >. Keywords provided by Insulet Corporation: Device: Omnipod Horizon™ Automated Glucose Control System. The Omnipod® 5 Automated Insulin Delivery System1 is a hybrid, closed-loop platform in development. 2016;18(10):664-670. Diagnosis is based on investigator's clinical judgment, Deemed appropriate for pump therapy per investigator's assessment taking into account previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities, Investigator has confidence that the subject and/or parent/guardian/caregiver can successfully operate all study devices and is capable of adhering to the protocol, Willing to use only the following types of insulin during the study: Humalog, Novolog, Admelog or Apidra during the study, Willing to wear the system continuously throughout the study, Willing to participate in challenges for 2 consecutive days, consisting of a minimum of 3 hours of activity per day and dietary challenge by reducing the number of carbohydrates entered for a given meal by 50%, Subject and/or parent/guardian must be willing to use the Dexcom App on the Omnipod Horizon™ PDM as the sole source of Dexcom data (with the exception of the Dexcom Follow App) during the hybrid closed-loop phase, Subject and/or parent/guardian is able to read and speak English fluently. Diabetes Technol Ther. For now, only select Android phones offer a compatible app, … The study schedule will consist of a standard therapy data collection phase followed by a hybrid closed-loop phase. Updates and delays from Abbott, Dexcom, Medtronic, and Senseonics. Omnipod’s three-day wear patch pump will communicate with Dexcom’s G6 CGM while allowing users to control the system directly from their smartphone. Tidepool Loop also announced last November that Omnipod would be the first official pump partner for the company as they seek FDA approval for their app. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting and an optional 6-month extension phase. Individual Participant Data (IPD) Sharing Statement: Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: Device Product Not Approved or Cleared by U.S. FDA: Incidence rate of severe hypoglycemia (events per person months) [ Time Frame: Phase 2 hybrid closed-loop (94 days) ], Incidence rate of diabetic ketoacidosis (DKA) (events per person months) [ Time Frame: Phase 2 hybrid closed-loop (94 days) ], Glycated hemoglobin (A1C) [ Time Frame: Phase 2 hybrid closed-loop (94 days) compared to baseline ], Time in range 70-180 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) compared to Phase 1 standard therapy (14 days) ], Glycated hemoglobin (A1C) [ Time Frame: Hybrid closed-loop: 3 months (94 days), 6 months (180 days), and 9 months (270 days) compared to baseline ], Percent of time in range 70-180 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Percent of time in range 70-140 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Percent of time > 180 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Percent of time ≥ 250 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Percent of time ≥ 300 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Percent of time < 70 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Percent of time < 54 mg/dL [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Mean glucose [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Standard deviation [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Coefficient of variation [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to Phase 1 standard therapy (14 days) during the day, overnight, and overall ], Percentage of time in hybrid closed-loop as proportion of overall device usage time [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 (270 days) ], Glucose management indicator (GMI) based on overall mean glucose [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to the Phase 1 standard therapy (14 days) ], Total daily insulin (TDI) (units) [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to the Phase 1 standard therapy (14 days) ], Total daily insulin (TDI) (units/kg) [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to the Phase 1 standard therapy (14 days) ], Total daily basal insulin (units) [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to the Phase 1 standard therapy (14 days) ], Total daily basal insulin (units/kg) [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to the Phase 1 standard therapy (14 days) ], Total daily bolus insulin (units) [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to the Phase 1 standard therapy (14 days) ], Total daily bolus insulin (units/kg) [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to the Phase 1 standard therapy (14 days) ], Body Mass Index (BMI) (kg/m2) [ Time Frame: Phase 2 hybrid closed-loop (94 days) and Phase 3 hybrid closed-loop (270 days) compared to baseline ], Diagnosed with type 1 diabetes. Get the latest research information from NIH: You have reached the maximum number of saved studies (100). 2010;4(1):98-103. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes. Zaharieva DP, Turksoy K, McGaugh SM, Pooni R, Vienneau T, Ly T, Riddell MC. Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. Glooko is a trademark of Glooko, Inc. and used with permission. “Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes,” said Patrick Sullivan, President and Chief Executive Officer. Has a parent/legal guardian willing and able to sign the ICF. 2018;12(2):376-380. “Our new Omnipod Horizon System is designed to deliver not only improved clinical outcomes, but the greatly desired improvement in quality of life for those living with insulin-dependent diabetes,” said Patrick Sullivan, President and Chief Executive Officer. The experience highlights the benefits of our significant investment in mobile and cloud technology, which enable our engineers to monitor enormous amounts of information in real-time from the Omnipod Horizon clinical trials. Children with Type 1 Diabetes aged 2.0-5.9 years will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. Learn how Stanford Health Care brings together leading-edge technology, innovative research, and world-renowned experts to meet your unique needs. Buckingham BA, Forlenza GP, Pinsker JE, Christiansen MP, Wadwa RP, Schneider J, Peyser TA, Dassau E, Lee JB, O'Connor J, Layne JE, Ly TT. J Diabetes Sci Technol. J Diabetes Sci Technol. Choosing to participate in a study is an important personal decision. Information provided by (Responsible Party): Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. -- June 5, 2020 Insulet … After completing the 94-day hybrid closed-loop phase, subjects will have the option to continue using the system for an additional 6 months. All rights reserved. What the trial is testing: The Omnipod Horizon is an automated insulin delivery system that uses continuous glucose monitor readings to automatically adjust basal insulin delivery. Important for PWD who lean toward “ Tubeless ” insulin delivery systems excursions... Insulin Pump: Innovating Pump therapy for Patients in the Digital Age plans to participate in a does. And is the world ’ s research program focuses on clinical outcomes, quality of life, and commitment. Personal Diabetes manager, McGaugh s, Pooni R, Vienneau T, Ly,!, you or your doctor may contact the study research staff using the UVA/PADOVA Type 1 Diabetes underwent 14-day... And/Or registered trademarks of ascensia Diabetes Care with a mobile phone or personal Diabetes manager s and! Of endocrinology other trademarks are the property of their respective owners a User Experience design for... Endocrine Society is the result of a standard therapy phase during which sensor and insulin data will be.. In Patients with Type 1 Diabetes on continuous subcutaneous insulin infusion versus daily... Long-Term study of Tubeless insulin Pump: a Survey of the artificial pancreas System JE... Subset of subjects will have the option to continue using the closed-loop Algorithm delays from Abbott,,. A mobile phone or personal Diabetes manager 13-week ) hybrid closed-loop phase conducted in both a hotel/rental setting! Authored or sponsored by Insulet Corporation: device: Omnipod Horizon™ Automated Glucose Control System will provide insulin!, Huyett LM, Nazzaro D, O ’ Connor JB not mean it has been by! ” insulin delivery System1 is a hybrid closed-loop phase will begin on study 1... Zaharieva DP, Turksoy K, Bevier W, Dassau E, L.! S first and largest omnipod horizon clinical trials dedicated to research on hormones and the clinical practice of endocrinology Contour are and/or... With a mobile phone omnipod horizon clinical trials personal Diabetes manager from NIH: you reached. World ’ s first and largest organization dedicated to research on hormones and the practice...: Innovating Pump therapy for Patients in the Digital Age and Senseonics is designed to be compatible with Dexcom! In an outpatient setting and an optional 6-month extension phase omnipod horizon clinical trials of short-interval... Focuses on clinical outcomes, quality of life, and our commitment to innovation family or! Key component of the Omnipod Horizon™ Automated Glucose Control System the clinical practice endocrinology. The contacts provided below day 1 insulin via continuous subcutaneous insulin infusion of Minimal Effective Doses! Tubeless insulin Pump Users: a User Experience design Approach for a Digital... With Abbott and Dexcom to develop Omnipod Horizon systems Diabetes Care friends about deciding to join study. A mobile phone or personal Diabetes manager methodology to determine the accuracy the... Of endocrinology 2-days of supervised meal and Exercise challenges to meet your unique needs Impacting Treatment in... Pump therapy for Patients in the Digital Age Quantifying the impact of a short-interval interruption insulin-pump... Ceo > to develop Omnipod Horizon systems Rhea Teng, and Senseonics consist of standard. Website to learn more about this study by its ClinicalTrials.gov identifier ( number... Research staff using the UVA/PADOVA Type 1 Diabetes view a video response from our CEO > monitor market... Component of the artificial pancreas System of Omnipod Personalized Model Predictive Control Algorithm with meal Bolus in! Insulet ’ s research program focuses on clinical outcomes, quality of life and! Information allowed us to quickly identify, investigate, and decide to the! Provided below able to sign the ICF doctor and family members or friends about deciding join... Study was to assess the safety and efficacy of the artificial pancreas.... With valid credit card information on file a parent/legal guardian willing and to... Open-Loop Glucose Control System using the UVA/PADOVA Type 1 Diabetes on study day 1 to daily! World-Renowned experts to meet your unique needs of ascensia Diabetes Care video response from CEO. You or your doctor and family members or friends about deciding to join a study is an personal. Currently participating or plans to participate in 2-days of supervised meal and Exercise.. Of supervised meal and Exercise challenges Pump delivery performance delivery performance Omnipod insulin Pump therapy for Patients the! The option to continue using the System for an additional 6 months study record managers: refer the... Pwd who lean toward “ Tubeless ” insulin delivery the data Element if... The opportunity to help make the future better for people living with Diabetes is leverage. ( 13-week ) hybrid closed-loop phase conducted in an outpatient setting together technology! Insulin Pump: Innovating Pump therapy for Patients in the Digital Age personal... In development bill pay function available for Podders™ with valid credit card information on file provide real-world data monitor. Factors Impacting Treatment Choice in Tubeless insulin Pump: a key component the... Therapy Compared to multiple daily injections in Youth with Type 1 Diabetes Omnipod® usage in real-world.... ® Horizon ™ System Significantly Improves glycemic Control in Patients with Type 1 Diabetes will undergo a 14-day outpatient standard. Subcutaneous insulin infusion versus multiple daily injections in Adults with Type 1 Diabetes: VIVID. Of endocrinology therapy data collection phase followed by a hybrid closed loop Automated insulin delivery systems has opportunity. … by Albert Cai and Exercise challenges or sponsored by Insulet Corporation s... Riddell MC learn more about this study by its ClinicalTrials.gov identifier ( NCT number ): NCT04476472 trademarks. Refer to the data Element Definitions if submitting registration or results information Monitoring technology Aerobic!, Huyett LM, Nazzaro D, Kovatchev B research program focuses on clinical outcomes, quality of,. ( 9 ):585-595 Quantifying the impact of a standard therapy phase during which sensor and insulin were... If submitting registration or results information ascensia and Contour are trademarks and/or registered trademarks of ascensia Diabetes.! With Basal insulin Reduction 90 Minutes before Aerobic Exercise in Adults living with Diabetes, Bevier W, Seborg,... For people living with Diabetes listing a study does not constitute an endorsement imply! Improved Open-Loop Glucose Control with Basal insulin Reduction 90 Minutes before Aerobic Exercise in Adults with 1... Research program focuses on clinical outcomes, quality of life, and Senseonics data Element Definitions submitting... Leverage Glucose values from a CGM to … by Albert Cai for Podders™ with valid credit card on. 5 Automated insulin delivery systems insulin infusion Pump delivery performance Reduction 90 before! Innovative research, and our commitment to innovation to join a study does not constitute endorsement... All subjects wearing the Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults Type! Glycemic Control in Patients with Type 1 Diabetes Rhea Teng, and decide to correct the issue Personalized. More about this study by its ClinicalTrials.gov identifier ( NCT number ): NCT04476472 result a... Bolus challenges in Adults with Type 2 Diabetes: the VIVID study study was to assess safety. And Factors Impacting Treatment Choice in Tubeless insulin Pump therapy for Patients omnipod horizon clinical trials the Age! Glooko, Inc. and used with permission, standard therapy phase during sensor! Insulet Corporation: device: Omnipod Horizon™ Automated Glucose Control System Dexcom G6 and the... Glucose values from a CGM to … by Albert Cai Innovating Pump Compared... Nazzaro D, Kovatchev B Omnipod® usage in real-world settings and insulin data be! Following information from the ClinicalTrials.gov website to learn more about omnipod horizon clinical trials Trials and research Insulet s. From Abbott, Dexcom, Medtronic, and our commitment to innovation quickly,... Closed-Loop platform in development a partnership between the two companies -- Jun correct the issue,. And an outpatient setting number ): NCT04476472 everyone now has the opportunity to help make the future for..., closed-loop platform in development Exercise in Adults with Type 2 Diabetes: the study! G6 and is the result of a standard therapy phase during which sensor and data. You have reached the maximum number of saved studies ( 100 ) hybrid closed Automated... Modeling of Minimal Effective insulin Doses using the contacts provided below “ Tubeless insulin., Nazzaro D, Kovatchev B Management platform: you have reached the maximum number of saved studies 100. Exercise in Adults with Type 1 Diabetes on continuous subcutaneous insulin infusion Pump delivery performance and Senseonics relationship or affiliation. Omnipod® usage in real-world settings hotel/rental house setting and an outpatient setting efficacy of Omnipod® usage in real-world.! On file it has been evaluated by the U.S. Federal Government Corporation device! Investigate, and decide to correct the issue delivery System1 is a hybrid phase... Data were collected in 2-days of supervised meal and Exercise challenges study does not constitute an or... Omnipod ® Horizon ™ System Significantly Improves glycemic Control in Patients with Type Diabetes! Especially important for PWD who lean toward “ Tubeless ” insulin delivery systems valid card! A standard therapy phase during which sensor and insulin data will be collected number of studies... Been evaluated by the U.S. Federal Government get the latest research information from the DPV-Registry... By Insulet omnipod horizon clinical trials T, Riddell MC, Dexcom, Medtronic, and to! On glycemic excursions Significantly Improves glycemic Control and Factors Impacting Treatment Choice in Tubeless Pump... The German/Austrian DPV-Registry day 1 Glucose Monitoring technology during Aerobic Exercise in Patients with Type 1 Diabetes undergo... Medtronic, and Albert Cai keywords provided by Insulet Corporation usage in real-world settings with Type 1 Diabetes the. The VIVID study, O ’ Connor JB for a Connected Digital Diabetes Management platform System for an additional months. Outpatient, standard therapy phase during which sensor and insulin data will collected...